FDA launches new plan for developing rare disease drugs
The FDA has launched a new plan to change how drugs for rare diseases are developed and reviewed. The agency says rules should fit the small number of patients with each disease. It will hold a public meeting on Oct. 28 to hear from patients, families and drug makers.
The Food and Drug Administration has launched a new effort to change how drugs and biologics for rare diseases are developed and reviewed, KHQ and PharmTech reported.
The Rare Disease Framework Initiative aims to build an approach that fits the realities of rare disease research, including small numbers of patients, KHQ said. PharmTech said a new white paper describes the plan, which covers everything from early talks with drug makers to rules after approval.
About 30 million Americans live with a rare disease, PharmTech reported, citing the white paper. Only about 5% of rare diseases have an approved treatment, both outlets said.
"Americans with rare diseases cannot afford a regulatory system that treats every condition the same," Health Secretary Robert F. Kennedy Jr. said, according to KHQ.
Acting FDA Commissioner Kyle Diamantas said patients and families "have few or no approved treatment options," KHQ reported. He said the FDA would build a more consistent and predictable approach while keeping its standards.
The effort is led by the FDA's Rare Disease Innovation Hub, PharmTech said. Its director, Amy Comstock Rick, said the new framework "will enhance consistency and predictability for both sponsors and for patients," according to KHQ.
The FDA said it will use risk-based approaches to review how drugs are made and to inspect plants before approval, both outlets reported. PharmTech said the white paper does not yet say what those approaches will look like.
The FDA will hold a public meeting on Oct. 28 at its White Oak campus in Maryland to gather feedback, both outlets reported. KHQ said the Reagan-Udall Foundation will run the meeting. The FDA also plans roundtables and a formal request for information, PharmTech said.
The process could lead to new or revised guidance and changes to regulations, both outlets reported.
What we know: The FDA has launched a rare disease plan and set an Oct. 28 meeting.
What we don't: What specific rule changes will come out of it.
Where outlets agree KHQ and PharmTech both report that the FDA launched the Rare Disease Framework Initiative and will hold a public meeting Oct. 28 at its White Oak campus.
Where they differ The outlets cited here report the same key facts so far.